Is Genprex, Inc. (GNPX) a Buy, Sell, or Hold?
NASDAQ : GNPX
Genprex, Inc.
$4.495 USD
$0.3 (7.28%)
- Volume
- 139.81K
- Average Volume
- 68.68K
- Market Capitalization
- $2.27M
- P/E Ratio
- -0.01
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $1210.00
- Year Low
- $4.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.61
Company Overview
NASDAQ
Ryan Confer
Biotechnology
Healthcare
GNPX
13
US
USD
Liquidity Metrics
0.00
5.61
5.61
5.38
0.00
Sales & Valuation
-$
0.00
0.08
-0.16
-45.22
Profitability
-$382.8
-$16.23M
0.00%
0.00%
-247.33%
-82.37%
P/E Metrics
-0.01
0.00
0.00
Analyst Price Target & Rating
2/5
1 Analysts
%
Financial Health Scores
-13.41
2/9
$15.45M
$20.31M
$3.38M
-$15.99M
Key Metrics (TTM)
-$15.93M
0.00
1.00
5.61
-247.33%
-94.62%
-1263.27%
-675.35%
0 days
Company Executives
| Name | Title |
|---|---|
| David Schloss | Senior Vice President of Human Resources |
| Greg Jancarik | Senior Director & Corporate Controller |
| Celina Laney | Chief of Staff |
| Mark S. Berger | Chief Medical Officer |
| Thomas C. Gallagher | Senior Vice President of Intellectual Property & Licensing |
| Suzanne Thornton-Jones | Senior Vice President of Regulatory Affairs & Quality |
| Ryan Confer | President, Chief Executive Officer, Chief Financial Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Genprex, Inc. (NASDAQ:GNPX) Stock
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas. ...
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies
2026-08-03 07:00:00
Collaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in Oncology Validation Studies Aim to Optimize Clinical Trial Patient Selection Criteria AUSTIN, Texas, Aug. 3, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker.
2026-06-22 09:00:00
Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq® AUSTIN, Texas, June 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that The Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance to Genprex for a patent covering the use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with either PD-1 or PD-L1 antibodies for the treatment of both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). "Securing this patent strengthens Genprex's intellectual property portfolio, providing crucial protection for the therapeutic combinations currently being evaluated in the Acclaim-3 clinical trial," said Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing at Genprex.
Genprex to Participate at BIO International Convention 2026
2026-06-17 09:00:00
The BIO International Convention Brings Together More Than 20,000 Biotech Industry Leaders From Around The World AUSTIN, Texas, June 17, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its team will be attending and participating at the BIO 2026 International Convention taking place June 22-25, 2026 in San Diego, California. In attendance from Genprex's executive leadership team will be Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing.
2026-05-26 08:00:00
Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine AUSTIN, Texas, May 26, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract details positive clinical data from studies of predictive biomarkers in patients receiving its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of lung cancer.
2026-05-14 08:00:00
Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks AUSTIN, Texas, May 14, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data on the Company's diabetes gene therapy drug candidate at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. The collaborators presented preclinical data demonstrating that the diabetes gene therapy (Pdx1/MafA gene therapy, PM or GPX-002) can reverse hyperglycemia in Type 2 diabetic (T2D) mouse models.
Frequently Asked Questions
-
What is the current Genprex, Inc. (GNPX) stock price?
-
Genprex, Inc.(NASDAQ:GNPX) stock price is $4.495 in the last trading session. During the trading session, GNPX stock reached the peak price of $1210 while $4 was the lowest point it dropped to. The percentage change in GNPX stock occurred in the recent session was 7.28% while the dollar amount for the price change in GNPX stock was $0.3.
-
GNPX's industry and sector of operation?
-
The NASDAQ listed GNPX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GNPX?
-
David Schloss | Senior Vice President of Human Resources
Greg Jancarik | Senior Director & Corporate Controller
Celina Laney | Chief of Staff
Mark S. Berger | Chief Medical Officer
Thomas C. Gallagher | Senior Vice President of Intellectual Property & Licensing -
How many employees does GNPX have?
-
Number of GNPX employees currently stands at 13. GNPX operates from 3300 Bee Cave Road, Austin, TX 78746, US.
-
Link for GNPX official website?
-
Official Website of GNPX is: https://www.genprex.com
-
How do I contact GNPX?
-
GNPX could be contacted at phone #877 774 4679 and can also be accessed through its website. GNPX operates from 3300 Bee Cave Road, Austin, TX 78746, US.
-
How many shares of GNPX are traded daily?
-
The average number of GNPX shares traded daily for last 3 months was 68.68K.
-
What is the market cap of GNPX currently?
-
The market value of GNPX currently stands at $2.27M with its latest stock price at $4.495